canagliflozin sold brand name invokana among others medication used treat type used together exercise recommended type taken common side effects include vaginal yeast infections nausea constipation urinary tract serious side effects may include low blood sugar fourniers gangrene leg amputation kidney problems high blood potassium low blood diabetic ketoacidosis may occur despite nearly normal blood sugar use pregnancy breastfeeding canagliflozin sodiumglucose works increasing amount glucose lost canagliflozin approved medical use united states european union australia world health organizations list essential commonly prescribed medication united states million canagliflozin indicated used diet exercise lower blood sugar adults type diabetes reduce risk major heartrelated events heart attack stroke death people type diabetes known heart disease reduce risk endstage kidney disease worsening kidney function heartrelated death hospitalized heart failure certain people type diabetes diabetic kidney canagliflozin antidiabetic medication used improve blood sugar control people type diabetes thirdline medication per british national formulary also less preferred sulfonylurea american diabetes association european association study diabetes consider either inhibitor receptor agonist reasonable second line medication heart canagliflozin decreases levels given combination metformin combination metformin sulfonylurea combination metformin pioglitazone combination insulin initial levels added metformin canagliflozin appear worse sitagliptin glimepiride reducing levels canagliflozin maybe better sitagliptin glimiperide decreasing unclear whether unique cardiovascular benefits beyond lowering blood although canagliflozin produces beneficial effects hdl cholesterol also shown increase ldl cholesterol produce change total evidence shows apart positive effects glycemic levels canagliflozin also reduces risk heart attacks heart inhibitors including canagliflozin reduce likelihood hospitalization congestive heart failure progression renal disease persons diabetes mellitus type reduce likelihood stroke heart attack persons diabetes mellitus type known atherosclerotic vascular canaglifozin contraindicated inhibitors canagliflozin associated increased incidence urinary tract infections fungal infections genital area elevations ldl cholesterol increased urination episodes low blood pressure rarely use canagliflozin associated necrotizing fasciitis perineum also called fournier concerns may also increase risk diabetic possible cardiovascular problems ongoing issue gliflozin prespecified endpoint cardiovascular safety canagliflozin clinical development program major cardiovascular events plus defined occurrence cardiovascular death nonfatal myocardial infarctions nonfatal strokes unstable angina leading hospitalization endpoint occurred people placebo group canagliflozin treated group nonetheless united states food drug administration fda advisory committee expressed concern regarding cardiovascular safety canagliflozin greater number cardiovascular events observed first days study subjects received canagliflozin compared received placebo suggesting early period increased cardiovascular risk addition increased risk stroke subjects received canagliflozin however none effects statistically significant additional cardiovascular safety data another ongoing study expected may fda issued warning certain diabetes drugs including canagliflozin may lead ketoacidosis condition body produces higher levels ketone bodies fda continuing investigate issue cautions patients stop taking canagliflozin without first talking september fda issued drug safety communication canagliflozin address risks bone fracture decreased bone density label warning fractures already included adverse reactions section however fda made addition warnings precautions section reflect new information placebo study advised health care professionals consider fracture risk factors prescribing canagliflozin patients disclose bone fracture risk factors doctors patients stop taking medication without first talking december fda issued another safety communication inhibitors indicating would require new warnings added canagliflozin label elevated blood acid levels urinary tract june fda strengthened warning risk acute kidney injury type diabetes medicines canagliflozin invokana invokamet dapagliflozin farxiga xigduo june report ongoing cardiovascular outcomes trial canagliflozin canvas revealed interim findings new safety concerns including heightened risk bone fracture found increase duration may fda announced going investigate safety issue related clinical trials found increase leg foot amputations mostly affecting toes people treated diabetes medicine canagliflozin invokana may fda concluded canagliflozin causes increased risk leg foot fda began requiring boxed warning added canagliflozin drug labels describe august fda removed requirement boxed lessen risk developing ketoacidosis serious condition body produces high levels blood acids called ketones surgery fda approved changes prescribing information inhibitor diabetes medicines recommend stopped temporarily scheduled surgery canagliflozin dapagliflozin empagliflozin stopped least three days ertugliflozin stopped least four days scheduled symptoms ketoacidosis include nausea vomiting abdominal pain tiredness trouble drug may increase risk dehydration combination diuretic increases renal excretion glucose treatment canagliflozin prevents renal reabsorption leading artifactual decreases serum therefore canagliflozin interfere use serum assay trade name glycomark measure postprandial glucose dosing adjustment also required concomitant therapy udpglucuronosyl transferase ugt inducers rifampin phenytoin phenobarbital canagliflozin inhibitor subtype sodiumglucose transport proteins responsible least renal glucose reabsorption remaining done blocking transporter causes grams blood glucose per day eliminated corresponding kilocalories additional water eliminated osmotic diuresis resulting lowering blood pressure mechanism associated low risk hypoglycaemia low blood glucose compared types antidiabetic drugs sulfonylurea derivatives taken mouth canagliflozin reaches highest blood plasma concentrations one two hours absolute bioavailability independently food intake bloodstream substance bound plasma proteins mainly albumin metabolized mainly oglucuronidation via enzymes hydroxylation lesser extent terminal half life hours mg dose hours mg dose excreted faeces mostly unchanged form urine mostly developed mitsubishi tanabe pharma marketed license janssen division johnson july european medicines agency ema approved paediatric investigation plan granted deferral waiver canagliflozin accordance ec regulation european parliament approved medical use european union november canagliflozin approved fda march became first inhibitor united canagliflozin approved medical use australia september httpsenwikipediaorgwikicanagliflozin